Twist Bioscience Corp
Financial highlights
| Metric | FY 09/30/25 | FY 09/30/24 | FY 09/30/23 | FY 09/30/22 | FY 09/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $376.6M | $313.0M | $245.1M | $203.6M | $132.3M |
| Cost of revenue | $185.6M | $179.6M | $155.4M | $119.3M | $80.6M |
| Selling, general & administrative | $247.0M | $218.4M | $189.7M | $212.9M | $135.9M |
| Research and development | $80.3M | $90.9M | $106.9M | $120.3M | $69.1M |
| Operating income | -$136.3M | -$220.8M | -$217.2M | -$234.8M | -$152.7M |
| Interest expense | — | $29,000 | $5,000 | $80,000 | $367,000 |
| Pretax income | -$77.0M | -$208.2M | -$203.5M | -$228.3M | -$154.0M |
| Income tax expense | $719,000 | $560,000 | $1.2M | -$10.4M | -$1.9M |
| Net income | -$77.7M | -$208.7M | -$204.6M | -$217.9M | -$152.1M |
| Balance Sheet | |||||
| Cash and equivalents | $183.0M | $226.3M | $286.5M | $378.7M | $465.8M |
| Current assets | $333.0M | $346.8M | $424.3M | $596.5M | $546.5M |
| Total assets | $641.9M | $614.3M | $776.4M | $961.4M | $702.1M |
| Current liabilities | $91.4M | $71.0M | $73.3M | $90.7M | $63.1M |
| Total liabilities | $168.9M | $141.6M | $153.0M | $172.0M | $121.3M |
| Total debt | — | — | — | — | $833,000 |
| Stockholders' equity | $473.0M | $472.7M | $623.4M | $789.4M | $580.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$47.6M | -$64.1M | -$142.5M | -$124.4M | -$112.2M |
| Depreciation and amortization | $24.9M | $31.4M | $29.3M | $16.5M | $9.8M |
| Stock-based compensation | $64.5M | $50.9M | $30.3M | $79.7M | $37.0M |
| Capital expenditure | $28.0M | $5.1M | $27.8M | $101.9M | $27.1M |
| Free cash flow | -$75.6M | -$69.2M | -$170.3M | -$226.2M | -$139.3M |
| Impairments | $0 | $44.9M | $6.8M | $0 | $0 |
Shares outstanding 62.3M · Free float 96.9%
Annual filing data through FY ended September 30, 2025; float as of July 14, 2026.